The 36-month beta value for GRI is also noteworthy at -1.68. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GRI is 2.14M, and at present, short sellers hold a 4.91% of that float. The average trading volume of GRI on May 22, 2025 was 421.69K shares.
GRI) stock’s latest price update
The stock price of GRI Bio Inc (NASDAQ: GRI) has dropped by -8.70 compared to previous close of 1.38. Despite this, the company has seen a fall of -13.10% in its stock price over the last five trading days. globenewswire.com reported 2025-05-21 that Live webcast on Wednesday, May 28 th at 4:00 PM ET LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Wednesday, May 28, 2025 at 4:00 PM ET. As part of the event, Dr. Hertz will provide a corporate overview and business outlook.
GRI’s Market Performance
GRI’s stock has fallen by -13.10% in the past week, with a monthly drop of -31.52% and a quarterly drop of -82.14%. The volatility ratio for the week is 9.71% while the volatility levels for the last 30 days are 14.81% for GRI Bio Inc The simple moving average for the last 20 days is -23.82% for GRI’s stock, with a simple moving average of -85.25% for the last 200 days.
Analysts’ Opinion of GRI
Many brokerage firms have already submitted their reports for GRI stocks, with H.C. Wainwright repeating the rating for GRI by listing it as a “Buy.” The predicted price for GRI in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on December 09, 2024 of the previous year 2024.
GRI Trading at -54.68% from the 50-Day Moving Average
After a stumble in the market that brought GRI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.79% of loss for the given period.
Volatility was left at 14.81%, however, over the last 30 days, the volatility rate increased by 9.71%, as shares sank -26.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -79.33% lower at present.
During the last 5 trading sessions, GRI fell by -15.17%, which changed the moving average for the period of 200-days by -85.17% in comparison to the 20-day moving average, which settled at $1.6525. In addition, GRI Bio Inc saw -91.05% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GRI
The total capital return value is set at -2.01. Equity return is now at value -468.00, with -217.11 for asset returns.
Based on GRI Bio Inc (GRI), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -72.36.
Currently, EBITDA for the company is -8.23 million with net debt to EBITDA at 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
In summary, GRI Bio Inc (GRI) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
